Show simple item record

dc.contributor.authorLanfermann, Christian
dc.contributor.authorWintgens, Sebastian
dc.contributor.authorEbensen, Thomas
dc.contributor.authorKohn, Martin
dc.contributor.authorLaudeley, Robert
dc.contributor.authorSchulze, Kai
dc.contributor.authorRheinheimer, Claudia
dc.contributor.authorHegemann, Johannes H
dc.contributor.authorGuzman, Carlos Alberto
dc.contributor.authorKlos, Andreas
dc.date.accessioned2021-08-04T10:52:41Z
dc.date.available2021-08-04T10:52:41Z
dc.date.issued2021-06-06
dc.identifier.citationVaccines (Basel). 2021 Jun 6;9(6):609. doi: 10.3390/vaccines9060609.en_US
dc.identifier.issn2076-393X
dc.identifier.pmid34204170
dc.identifier.doi10.3390/vaccines9060609
dc.identifier.urihttp://hdl.handle.net/10033/622975
dc.description.abstractChlamydia trachomatis is the most frequent sexually-transmitted disease-causing bacterium. Urogenital serovars of this intracellular pathogen lead to urethritis and cervicitis. Ascending infections result in pelvic inflammatory disease, salpingitis, and oophoritis. One of 200 urogenital infections leads to tubal infertility. Serovars A-C cause trachoma with visual impairment. There is an urgent need for a vaccine. We characterized a new five-component subunit vaccine in a mouse vaccination-lung challenge infection model. Four recombinant Pmp family-members and Ctad1 from C. trachomatis serovar E, all of which participate in adhesion and binding of chlamydial elementary bodies to host cells, were combined with the mucosal adjuvant cyclic-di-adenosine monophosphate. Intranasal application led to a high degree of cross-serovar protection against urogenital and ocular strains of C. trachomatis, which lasted at least five months. Critical evaluated parameters were body weight, clinical score, chlamydial load, a granulocyte marker and the cytokines IFN-γ/TNF-α in lung homogenate. Vaccine antigen-specific antibodies and a mixed Th1/Th2/Th17 T cell response with multi-functional CD4+ and CD8+ T cells correlate with protection. However, serum-transfer did not protect the recipients suggesting that circulating antibodies play only a minor role. In the long run, our new vaccine might help to prevent the feared consequences of human C. trachomatis infections.en_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectChlamydia trachomatisen_US
dc.subjectCtad1en_US
dc.subjectPmpen_US
dc.subjectc-di-AMPen_US
dc.subjectimmune responseen_US
dc.subjectlung infectionen_US
dc.subjectmouse modelen_US
dc.subjectpolymorphic membrane proteinsen_US
dc.subjectsexually-transmitted diseaseen_US
dc.subjectvaccineen_US
dc.titleProphylactic Multi-Subunit Vaccine against Chlamydia trachomatis In Vivo Evaluation in Mice.en_US
dc.typeArticleen_US
dc.contributor.departmentHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.en_US
dc.identifier.journalVaccinesen_US
dc.source.volume9
dc.source.issue6
refterms.dateFOA2021-08-04T10:52:41Z
dc.source.journaltitleVaccines
dc.source.countrySwitzerland


Files in this item

Thumbnail
Name:
Lanfermann et al.pdf
Size:
18.81Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International